title: Developing long-acting growth hormone formulations.
abstract: Daily recombinant growth hormone (GH) restores normal growth and body composition in GH-deficient children and adults; however, daily injections are inconvenient and can be distressing for some children. On top of this compliance is a problem in up to 75% of children. Developing long-acting GH formulations has proved challenging, and questions remain regarding safety and efficacy. In this review, we focus on the rationale for generating long-acting GH agonists and the technologies being developed to deliver prolonged exposure to GH.
authors.affiliation: Academic Unit of Diabetes, Endocrinology and Reproduction, University of Sheffield, Sheffield, UK.
authors.forename: Pippa
authors.initials: P
authors.lastname: Cawley
authors.forename: Ian
authors.initials: I
authors.lastname: Wilkinson
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Ross
mesh_terms: D000328:Adult; D001823:Body Composition; D002626:Chemistry, Pharmaceutical / Q000379:methods; D002648:Child; D015195:Drug Design; D019382:Human Growth Hormone / Q000819:agonists / Q000737:chemistry / Q000172:deficiency / Q000627:therapeutic use*; D006801:Humans; D011993:Recombinant Fusion Proteins / Q000737:chemistry
chemical_list: D011993:Recombinant Fusion Proteins; D019382:Human Growth Hormone